CD8A and neoplasm: Consistent with previous findings (41–43), pathological examination revealed that patients with a high frequency of CD8+ T cells in tumor tissue (hot tumors: ≥ 12.0/field) showed a better PFS during nivolumab treatment compared with those with a low frequency (cold tumors: < 12.0/field) (Supplemental Figure 12A).